Current Report Filing (8-k)
October 18 2021 - 02:31PM
Edgar (US Regulatory)
false000087401500008740152021-10-172021-10-17
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 17,
2021
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125
|
|
33-0336973
|
(Commission File No.)
|
|
(IRS Employer Identification
No.)
|
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number,
including area code: (760)
931-9200
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class
|
|
Trading
symbol
|
|
Name of each
exchange on which registered
|
Common Stock,
$.001 Par Value
|
|
“IONS”
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(Section 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (Section 240.12b-2 of this chapter).
|
Emerging growth
company
☐ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
On October 17, 2021, Ionis Pharmaceuticals, Inc. issued a press
release announcing that Ionis’ partner, Biogen, announced topline
results from its placebo-controlled pivotal Phase 3 VALOR study of
tofersen, an investigational antisense medicine being evaluated for
people with superoxide dismutase 1 (SOD1) amyotrophic lateral
sclerosis (ALS).
A copy of this press release is attached as Exhibit 99.1 to this
Current Report and incorporated herein by reference.
Item 9.01. |
Financial Statements and
Exhibits.
|
(d) Exhibits.
Exhibit No.
|
Description
|
|
Press Release dated October 17, 2021.
|
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL
document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly
authorized.
|
Ionis Pharmaceuticals, Inc.
|
|
|
Dated: October 18,
2021
|
By:
|
/s/ Patrick R. O’Neil
|
|
|
Patrick R. O’Neil
|
|
|
Executive Vice President, Chief
Legal Officer and General Counsel
|
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2022 to May 2022
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From May 2021 to May 2022